rs193929374 — GCK GCK Ala378Val (MODY2)

Pathogenic missense variant in glucokinase that raises the glucose set-point for insulin secretion, causing mild stable fasting hyperglycemia (heterozygous MODY2) or severe permanent neonatal diabetes (homozygous)

See your personal result for GCK

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GCK Ala378Val — When Your Glucose Sensor Is Set Too High

Inside every pancreatic beta cell, a single enzyme acts as the body's glucose sensor: glucokinase11 glucokinase
Also called hexokinase IV; the rate-limiting enzyme for glucose phosphorylation in beta cells and hepatocytes. By catalyzing the first committed step of glycolysis — converting glucose to glucose-6-phosphate — glucokinase determines the blood glucose concentration at which insulin secretion is triggered. The Ala378Val substitution encoded by this variant disrupts that sensor, shifting the entire glucose threshold for insulin release upward. One copy of this variant (heterozygous state) causes GCK-MODY22 GCK-MODY
Maturity-onset diabetes of the young type 2; also called MODY2. Characterized by lifelong mild fasting hyperglycemia from birth, autosomal dominant inheritance, and low rates of vascular complications, the most common and benign form of monogenic diabetes.

The Mechanism

Alanine 378 sits within the catalytic core of glucokinase, close to the glucose binding site. The substitution of the small, nonpolar alanine with the bulkier valine residue impairs the enzyme's conformational flexibility and reduces its glucose-binding affinity and catalytic rate. In the homozygous state, the Ala378Val variant essentially abolishes glucokinase activity — enzyme kinetics studies show only 0.2% of wild-type activity when both alleles carry this substitution — 33 Njølstad et al. 2003 — homozygous Ala378Val: activity index 0.2% of wild-type, causing permanent neonatal diabetes with intrauterine growth retardation (Diabetes, PMID 14578306) leading to near-complete glucokinase deficiency and permanent insulin-dependent diabetes from birth.

In the heterozygous state, one functional copy of glucokinase remains. The beta cell still senses glucose, but the set-point is shifted: higher blood glucose concentrations are required before significant insulin secretion is triggered. This results in a stable, mild elevation of fasting blood glucose (typically 5.5–8.0 mmol/L, or 99–144 mg/dL) that is present from birth and does not progressively worsen. The condition is lifelong but largely stable.

The Evidence

GCK-MODY is one of the best-characterized forms of monogenic diabetes. The Osbak et al. 2009 review44 Osbak et al. 2009 review
Update on mutations in glucokinase (GCK) which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Human Mutation, 2009 catalogued 620 inactivating mutations across 1,441 families, establishing that heterozygous inactivating GCK mutations uniformly produce MODY2 while homozygous mutations cause permanent neonatal diabetes — a dose-response relationship that reflects the gene's haplosufficiency threshold.

Crucially, long-term follow-up data show that the chronic mild hyperglycemia of heterozygous GCK-MODY does not cause the vascular complications typically seen in type 2 diabetes. Pruhova et al. (2013) found no increase in carotid intima-media thickness in GCK-MODY patients compared with normoglycemic controls, despite decades of elevated fasting glucose. 55 Pruhova et al. 2013 — chronic mild hyperglycemia in GCK-MODY does not increase carotid intima-media thickness vs controls, confirming benign vascular course (PMID 24101925) The Ala378Val variant was specifically identified in multiple unrelated individuals with non-autoimmune, non-insulin-deficient monogenic diabetes and meets multiple ACMG/AMP pathogenicity criteria (PP1_Strong, PS4, PM5, PP2, PP3) as reviewed by the ClinGen Monogenic Diabetes Expert Panel in 2023.

Practical Actions

For heterozygous carriers, the clinical implication is that this is not type 1 or type 2 diabetes — it is a distinct condition with a fundamentally different prognosis. Insulin and oral hypoglycemics are generally not recommended for GCK-MODY in the non-pregnant state, as lowering glucose below the genetically elevated set-point can cause hypoglycemia without meaningful long-term benefit. The exception is pregnancy: if the fetus has not inherited the GCK mutation, maternal treatment may be warranted to avoid fetal overgrowth.

Genetic testing of first-degree relatives is important: GCK-MODY is autosomal dominant, so each parent, sibling, and child of a carrier has a 50% probability of carrying the same variant.

Interactions

The fasting glucose set-point in GCK-MODY is independent of, and additive with, common GWAS variants in the same pathway — including the GCK regulatory region (rs1799884) and the glucokinase regulatory protein gene GCKR (rs1260326). These common variants modulate fasting glucose at a population level by a few tenths of a mmol/L, while the Ala378Val pathogenic variant raises the set-point by approximately 1–2 mmol/L — orders of magnitude larger than any common variant effect. Compound heterozygosity with other GCK inactivating mutations, though theoretically possible, is extremely rare; homozygosity for Ala378Val produces the severe neonatal phenotype described by Njølstad et al.

Genotype Interpretations

What each possible genotype means for this variant.

GG Non-carrier Normal

No GCK Ala378Val variant — standard glucose set-point

You do not carry the GCK Ala378Val variant. Your glucokinase enzyme functions normally, and your pancreatic beta cells sense blood glucose at the standard threshold. The vast majority of people worldwide carry this genotype. Your fasting glucose is not affected by this variant.

AG GCK-MODY Carrier High Risk

One copy of Ala378Val — GCK-MODY, elevated glucose set-point

GCK Ala378Val was identified in the ClinGen Monogenic Diabetes Variant Curation Expert Panel's 2023 review in 9 unrelated individuals with non-autoimmune, non-insulin-deficient diabetes, meeting multiple ACMG/AMP criteria for pathogenic classification (PP1_Strong, PS4, PM5, PP2, PP3). The variant is absent from general population databases at meaningful frequency, consistent with its pathogenic nature.

The heterozygous phenotype — GCK-MODY — results from haploinsufficiency: one functional glucokinase allele is insufficient to set the glucose-sensing threshold at the wild-type level, but it is sufficient to prevent the severe insulin deficiency seen in the homozygous state. This produces a distinct and stable phenotype: fasting hyperglycemia that is present from birth and does not significantly worsen with age, unlike the progressive beta-cell failure of type 2 diabetes.

Individuals who have been misdiagnosed with type 2 diabetes or gestational diabetes based on glucose values alone should discuss GCK testing with a specialist, as the management of GCK-MODY differs substantially from T2DM. The key distinguishing features are: onset in childhood or young adulthood, mild stable fasting hyperglycemia (typically below 8 mmol/L), minimal postprandial glucose excursion (usually below 4 mmol/L rise on an oral glucose tolerance test), and a clear family history consistent with autosomal dominant inheritance.

AA Homozygous — Neonatal Diabetes Homozygous

Two copies of Ala378Val — near-complete glucokinase deficiency, severe neonatal diabetes

Homozygous GCK Ala378Val was first described by Njølstad et al. (2003, PMID 14578306) as part of a series of cases with permanent neonatal diabetes caused by glucokinase deficiency. The proband in that report was homozygous for Ala378Val, presenting with intrauterine growth retardation, small for gestational age birth, and permanent insulin-dependent diabetes from the neonatal period. Kinetics studies confirmed that Ala378Val in homozygous configuration retains only 0.2% of wild-type GCK activity — functionally equivalent to complete glucokinase null mutations.

Management requires lifelong insulin replacement. Unlike GCK-MODY (heterozygous), homozygous glucokinase deficiency is associated with significant vascular and metabolic complications if not treated adequately. Given the extreme rarity of this genotype, management should be guided by a specialized diabetes and metabolic genetics team.